<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888693</url>
  </required_header>
  <id_info>
    <org_study_id>M10-752</org_study_id>
    <nct_id>NCT00888693</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, tolerability and pharmacokinetics of ABT-288 in order to determine the
      maximum tolerated dose of ABT-288 in stable schizophrenic volunteers receiving treatment with
      an atypical antipsychotic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Exams, Brief Neurological Exams, Vitals, Orthostatic Vitals, ECG, Laboratory tests,</measure>
    <time_frame>Days -1 to 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics; optional CSF for arms 7, 8 &amp; 9</measure>
    <time_frame>Days -1 to 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extrapyramidal Symptom Rating Scale</measure>
    <time_frame>Day -1, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale</measure>
    <time_frame>Screening, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: CANTAB &amp; PANSS</measure>
    <time_frame>Screening, Day -1, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Pittsburgh Sleep Quality Index-Modified</measure>
    <time_frame>Day -1, Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo capsules administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo capsules administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo capsules administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT288 vs placebo administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo administered orally once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-288 vs placebo administered orally once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-288</intervention_name>
    <description>See Arm Description for details.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See Arm Description for details.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has signed informed consent;

          -  Current DSM-IV-TR diagnosis of schizophrenia;

          -  Clinically stable on the same single second-generation antipsychotic for the past 8
             weeks;

          -  Meets study-specific PANSS criteria;

          -  Willing and able to cooperate with cognitive testing

          -  Females are not pregnant, not breast-feeding;

          -  Females are post-menopausal or surgically sterile or practicing birth control;

          -  Males are surgically sterile or agree to be sexually inactive or use barrier method of
             birth control

        Exclusion Criteria:

          -  Subject has a substance dependence disorder that has not been in sustained remission
             for at least 1 year;

          -  Diagnosis of schizoaffective disorder;

          -  Bipolar disorder, manic episode, dementia, OCD, or drug-induced psychosis or current
             major depressive disorder;

          -  Diagnoses with mental retardation; acute psychosis hospitalization within past 6
             months;

          -  Current clozapine treatment; suicidal ideation or behavior;

          -  BMI of 39 or greater; current homicidal or violent ideation;

          -  Medical or CNS condition other than schizophrenia that could affect cognitive
             performance or testing; relevant drug sensitivity or allergy; positive urine screen
             for alcohol or drugs of abuse;

          -  Positive hepatitis or HIV test result;

          -  Recent clinically significant illness/infection or surgery;

          -  Recent blood product transfusion, donation or loss of 5 mL/kg of blood;

          -  Visual, hearing or communication disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Othman AA, Haig G, Florian H, Locke C, Gertsik L, Dutta S. The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers. Br J Clin Pharmacol. 2014 Jun;77(6):965-74. doi: 10.1111/bcp.12281.</citation>
    <PMID>24215171</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <name_title>Hana Florian, MD/Associate Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

